Napiorkowska-Baran K, Doligalska A, Drozd M, Czarnowska M, Laszczych D, Dolina M
Healthcare (Basel). 2024; 12(19).
PMID: 39408157
PMC: 11477378.
DOI: 10.3390/healthcare12191977.
Xu D, He Y, Liao C, Tan J
Biomed Rep. 2024; 20(6):96.
PMID: 38765860
PMC: 11099602.
DOI: 10.3892/br.2024.1784.
Xu D, Liao C, Tan J
Ann Med Surg (Lond). 2024; 86(2):850-855.
PMID: 38333285
PMC: 10849412.
DOI: 10.1097/MS9.0000000000001645.
Heidari Z, Naeimzadeh Y, Fallahi J, Savardashtaki A, Razban V, Khajeh S
Curr Mol Med. 2023; 24(9):1135-1151.
PMID: 37817529
DOI: 10.2174/0115665240258746230919165935.
Ahmadi S, Shabannezhad A, Kahrizi A, Akbar A, Safdari S, Hoseinnezhad T
Biomark Res. 2023; 11(1):60.
PMID: 37280670
PMC: 10242999.
DOI: 10.1186/s40364-023-00504-6.
Coagulation Factor IIIa () Knockdown in Zebrafish Leads to Defective Angiogenesis and Mild Bleeding Phenotype.
Subramaniam S, Liu J, Fletcher C, Ramchandran R, Weiler H
Front Cell Dev Biol. 2022; 10:852989.
PMID: 35386206
PMC: 8978257.
DOI: 10.3389/fcell.2022.852989.
Nano-Sized Extracellular Matrix Particles Lead to Therapeutic Improvement for Cutaneous Wound and Hindlimb Ischemia.
Ha S, Kim J, Savitri C, Choi D, Park K
Int J Mol Sci. 2021; 22(24).
PMID: 34948061
PMC: 8705579.
DOI: 10.3390/ijms222413265.
New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches.
Lopez-Pedrera C, Barbarroja N, Patino-Trives A, Collantes E, Aguirre M, Perez-Sanchez C
Front Immunol. 2019; 10:764.
PMID: 31040845
PMC: 6476988.
DOI: 10.3389/fimmu.2019.00764.
NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
Seidi K, Jahanban-Esfahlan R, Monhemi H, Zare P, Minofar B, Daei Farshchi Adli A
Oncogene. 2018; 37(29):3967-3980.
PMID: 29662195
PMC: 6053358.
DOI: 10.1038/s41388-018-0213-4.
Tumor vascular infarction: prospects and challenges.
Jahanban-Esfahlan R, Seidi K, Zarghami N
Int J Hematol. 2017; 105(3):244-256.
PMID: 28044258
DOI: 10.1007/s12185-016-2171-3.
Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy.
Abu El-Asrar A, Siddiquei M, Nawaz M, De Hertogh G, Mohammad G, Alam K
Mol Vis. 2016; 22:424-35.
PMID: 27168718
PMC: 4851855.
Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitis.
He H, Zhang J, Li Q
World J Gastroenterol. 2014; 20(23):7461.
PMID: 24966616
PMC: 4064091.
DOI: 10.3748/wjg.v20.i23.7461.
Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor.
Bravo M, Pinto M, Gonzalez I, Oliva B, Kato S, Cuello M
Endocrine. 2014; 48(1):309-20.
PMID: 24853881
DOI: 10.1007/s12020-014-0288-9.
P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway.
Zerrouqi A, Pyrzynska B, Brat D, Van Meir E
Cancer Res. 2014; 74(5):1371-8.
PMID: 24398474
PMC: 3947444.
DOI: 10.1158/0008-5472.CAN-13-1951.
Activation of blood coagulation in cancer: implications for tumour progression.
Lima L, Monteiro R
Biosci Rep. 2013; 33(5).
PMID: 23889169
PMC: 3763425.
DOI: 10.1042/BSR20130057.
Tissue factor-bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo.
Park J, Sharif A, Tschumperlin D, Lau L, Limbrey R, Howarth P
J Allergy Clin Immunol. 2012; 130(6):1375-83.
PMID: 22828416
PMC: 3511625.
DOI: 10.1016/j.jaci.2012.05.031.
(111)Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats.
Nalla A, Buch I, Sigvardt M, Bodholdt R, Kjaer A, Hesse B
Int J Mol Imaging. 2012; 2012:464810.
PMID: 22518302
PMC: 3299322.
DOI: 10.1155/2012/464810.
Tissue factor pathway inhibitor blocks angiogenesis via its carboxyl terminus.
Holroyd E, Delacroix S, Larsen K, Harbuzariu A, Psaltis P, Wang L
Arterioscler Thromb Vasc Biol. 2012; 32(3):704-11.
PMID: 22223730
PMC: 3288894.
DOI: 10.1161/ATVBAHA.111.243733.
Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure.
Holroyd E, White T, Pan S, Simari R
Front Biosci (Elite Ed). 2011; 4(1):392-400.
PMID: 22201881
PMC: 3904648.
DOI: 10.2741/e386.
2-Methoxyestradiol inhibits progesterone-dependent tissue factor expression and activity in breast cancer cells.
Quezada M, Diaz J, Henriquez S, Bravo M, Aranda E, Oliva B
Horm Cancer. 2011; 1(3):117-26.
PMID: 21761355
PMC: 10358164.
DOI: 10.1007/s12672-010-0019-5.